blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4074331

EP4074331 - COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  12.10.2023
Database last updated on 14.06.2024
FormerRequest for examination was made
Status updated on  14.04.2023
FormerThe application has been published
Status updated on  16.09.2022
Most recent event   Tooltip12.04.2024New entry: Despatch of examination report + time limit 
Applicant(s)For all designated states
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591 / US
[2022/42]
Inventor(s)01 / BAIK, Andrew
Tarrytown / US
02 / CYGNAR, Katherine
Tarrytown / US
 [2022/42]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[2022/42]
Application number, filing date22169278.308.12.2016
[2022/42]
Priority number, dateUS201562264702P08.12.2015         Original published format: US 201562264702 P
US201662379629P25.08.2016         Original published format: US 201662379629 P
[2022/42]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP4074331
Date:19.10.2022
Language:EN
[2022/42]
Search report(s)(Supplementary) European search report - dispatched on:EP24.06.2022
ClassificationIPC:A61K38/47, A61K38/46, C12N9/40, C12N9/42, A61P43/00
[2022/42]
CPC:
C12N9/2402 (EP,IL,US); A61K47/6815 (EP,IL,KR,US); A61K38/46 (CN);
A61K38/465 (EP,IL,KR,US); A61K38/47 (EP,CN,IL,KR,US); A61K47/6849 (EP,IL,KR,US);
A61K47/6879 (KR); A61P3/00 (EP,IL); A61P3/06 (EP,IL);
A61P3/08 (EP,IL); A61P43/00 (EP,CN,IL); C07K16/2896 (IL,US);
C12N9/2445 (EP,IL,KR,US); C12N9/2465 (EP,IL,KR,US); C12Y301/04 (EP,IL,US);
C12Y301/04041 (EP,IL,US); C12Y302/0102 (EP,IL,US); C12Y302/01021 (EP,IL,US);
C12Y302/01022 (EP,IL,US); C12Y302/01023 (EP,IL,US); C12Y302/01031 (EP,IL,US);
C12Y302/01076 (EP,IL,US); C07K2317/77 (IL,US); C07K2319/06 (IL,US);
C07K2319/74 (EP,IL,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/20]
Former [2022/42]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN ZUR INTERNALISIERUNG VON ENZYMEN[2022/42]
English:COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES[2022/42]
French:COMPOSITIONS ET MÉTHODES POUR L'INTERNALISATION D'ENZYMES[2022/42]
Examination procedure12.04.2023Examination requested  [2023/20]
12.04.2023Date on which the examining division has become responsible
16.05.2023Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
06.07.2023Amendment by applicant (claims and/or description)
11.10.2023Despatch of a communication from the examining division (Time limit: M04)
13.02.2024Reply to a communication from the examining division
11.04.2024Despatch of a communication from the examining division (Time limit: M04)
Parent application(s)   TooltipEP16829343.9  / EP3386534
EP20197224.7  / EP3782639
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
06.07.2023Request for further processing filed
06.07.2023Full payment received (date of receipt of payment)
Request granted
14.07.2023Decision despatched
Fees paidRenewal fee
21.04.2022Renewal fee patent year 03
21.04.2022Renewal fee patent year 04
21.04.2022Renewal fee patent year 05
21.04.2022Renewal fee patent year 06
20.12.2022Renewal fee patent year 07
19.12.2023Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]US2005142141  (PARDRIDGE WILLIAM M [US]) [X] 1-13 * the whole document *;
 [X]WO2006108052  (GENZYME CORP [US], et al) [X] 1-13 * the whole document * * claims 1-67 * * page 13, paragraph [34] - page 14, paragraph [42] *;
 [X]US2010183577  (STERN NAFTALI [IL], et al) [X] 1-13 * claims 1-21 * * the whole document *;
 [Y]US2013243775  (PAPADOPOULOS NICHOLAS J [US], et al) [Y] 1-13 * the whole document * * paragraphs [[41]] - [[45]] * * claims 1-33 * * examples 2-6 *;
 [Y]US2015322149  (BOHRMANN BERND [CH], et al) [Y] 1-13 * the whole document *;
 [IP]WO2016044947  (EXERKINE CORP [CA]) [IP] 1-13 * the whole document *;
 [E]EP3315606  (JAPAN CHEM RES [JP]) [E] 1-13 * the whole document * * paragraph [0086] ** claims 1-69 *
by applicantUS8878001
 WO2015026907
    - R.M. BOUSTANY, "Lysosomal storage diseases--the horizon expands", Nat. Rev. Neurol., (20131000), vol. 9, no. 10, pages 583 - 98
    - DESNICKSCHUCHMAN, "Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges", Annu. Rev. Genomics Hum. Genet., (20120000), vol. 13, pages 307 - 35
    - KOEBERL et al., "Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle", Mol. Genet. Metab., (20110000), vol. 103, no. 2, doi:10.1016/j.ymgme.2011.02.006, pages 107 - 12, XP028216120

DOI:   http://dx.doi.org/10.1016/j.ymgme.2011.02.006
    - ZHU et al., "Conjugation of mannose-6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in Pompe mice", J. Biol. Chem., (20040000), vol. 279, no. 48, pages 50336 - 41
    - MAGA et al., "Glycosylation-independent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in Pompe mice", J. Biol. Chem., (20130000), vol. 288, no. 3, doi:10.1074/jbc.M112.438663, pages 1428 - 38, XP055305638

DOI:   http://dx.doi.org/10.1074/jbc.M112.438663
    - S. HAKOMORI, "Glycosphingolipids in Cellular Interaction, Differentiation, and Oncogenesis", Annual Review of Biochemistry, (19810700), vol. 50, doi:10.1146/annurev.bi.50.070181.003505, pages 733 - 764, XP000579212

DOI:   http://dx.doi.org/10.1146/annurev.bi.50.070181.003505
    - J. MUENZER, "Early initiation of enzyme replacement therapy for the mucopolysaccharidoses", Mol. Genet. Metab., (20140200), vol. 111, no. 2, doi:10.1016/j.ymgme.2013.11.015, pages 63 - 72, XP028821359

DOI:   http://dx.doi.org/10.1016/j.ymgme.2013.11.015
    - SASISEKHARAN et al., "Glycomics approach to structure-function relationships of glycosaminoglycans", Ann. Rev. Biomed. Eng., (20141200), vol. 8, no. 1, pages 181 - 231
    - DIMAUROSPIEGEL, "Progress and problems in muscle glycogenosis", Acta Myol, (20111000), vol. 30, no. 2, pages 96 - 102
    - H. MAECKER et al., "The tetraspanin superfamily: molecular facilitators", FASEB J, (19970500), vol. 11, no. 6, pages 428 - 42, XP002037857
    - M. METZELAAR et al., "CD63 antigen. A novel lysosomal membrane glycoprotein, cloned by a screening procedure for intracellular antigens in eukaryotic cells", J. Biol. Chem., (19910000), vol. 266, pages 3239 - 3245, XP002037856
    - TULI et al., "Mechanism for amyloid precursor-like protein 2 enhancement of major histocompatibility complex class I molecule degradation", The Journal of Biological Chemistry, (20090000), vol. 284, pages 34296 - 34307
    - CLEVENGERKLINE, "Prolactin receptor signal transduction", Lupus, (20010000), vol. 10, no. 10, pages 706 - 18
    - GENTY et al., "Endocytosis and degradation of prolactin and its receptor in Chinese hamster ovary cells stably transfected with prolactin receptor cDNA", Mol. Cell Endocrinol., (19940000), vol. 99, no. 2, doi:10.1016/0303-7207(94)90011-6, pages 221 - 8, XP025826734

DOI:   http://dx.doi.org/10.1016/0303-7207(94)90011-6
    - FERLAND et al., "The effect of chloroquine on lysosomal prolactin receptors in rat liver", Endocrinology, (19840000), vol. 115, no. 5, pages 1842 - 9
    - TAJIMA et al., "Use of a Modified a-N-Acetylgalactosaminidase (NAGA) in the Development of Enzyme Replacement Therapy for Fabry Disease", Am. J. Hum. Genet., (20090000), vol. 85, no. 5, pages 569 - 580
    - OKABULLEID, "Forming disulfides in the endoplasmic reticulum", Biochim Biophys Acta, (20130000), vol. 1833, no. 11, doi:10.1016/j.bbamcr.2013.02.007, pages 2425 - 9, XP028683524

DOI:   http://dx.doi.org/10.1016/j.bbamcr.2013.02.007
    - MOWENDAVID, "Unconventional post-translational modifications in immunological signaling", Nat Immunol, (20140000), vol. 15, no. 6, pages 512 - 20
    - BLIXTWESTERLIND, "Arraying the post-translational glycoproteome (PTG", Curr Opin Chem Biol., (20140000), vol. 18, pages 62 - 9
    - BUTLERSPEARMAN, "The choice of mammalian cell host and possibilities for glycosylation engineering", Curr Opin Biotech, (20140000), vol. 30, pages 107 - 112
    - GHADERI et al., "Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation", Biotechnol Genet Eng Rev, (20120000), vol. 28, pages 147 - 75
    - WARD et al., Nature, (19890000), vol. 241, pages 544 - 546
    - HOLLIGER et al., PNAS USA, (19930000), vol. 90, pages 6444 - 6448
    - POLJAK et al., Structure, (19940000), vol. 2, pages 1121 - 1123
    - VINCENTMURINI, "Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates", Biotechnol. J., vol. 7, no. 20912, doi:10.1002/biot.201200250, pages 1444 - 1450, XP055069537

DOI:   http://dx.doi.org/10.1002/biot.201200250
    - SHIMAMOTO, "Peptibodies: A flexible alternative format to antibodies", MAbs, (20120000), vol. 4, no. 5, doi:10.4161/mabs.21024, pages 586 - 91, XP055484059

DOI:   http://dx.doi.org/10.4161/mabs.21024
    - S. CHIBA, "Molecular mechanism in alpha-glucosidase and glucoamylase", Biosci. Biotechnol. Biochem., (19970000), vol. 61, no. 8, doi:10.1271/bbb.61.1233, pages 1233 - 9, XP055664704

DOI:   http://dx.doi.org/10.1271/bbb.61.1233
    - HESSELINK et al., "Lysosomal dysfunction in muscle with special reference to glycogen storage disease type II", Biochim. Biophys. Acta, (20030000), vol. 1637, no. 2, doi:10.1016/S0925-4439(02)00229-6, pages 164 - 70, XP004414108

DOI:   http://dx.doi.org/10.1016/S0925-4439(02)00229-6
    - PRABAKARAN et al., "Mannose 6-phosphate receptor and sortilin mediated endocytosis of a-galactosidase A in kidney endothelial cells", PLoS One, (20120000), vol. 7, no. 6, pages 1 - 9
    - CHEN et al., "Fusion protein linkers: property, design and functionality", Adv Drug Deliv Rev, (20130000), vol. 65, no. 10, doi:10.1016/j.addr.2012.09.039, pages 1357 - 69, XP028737352

DOI:   http://dx.doi.org/10.1016/j.addr.2012.09.039
    - MA et al., Drug Metab. Dispos., (20081200), vol. 36, no. 12, pages 2506 - 12
    - KUEMMEL et al., Pathol. Res. Pract., (19970000), vol. 193, no. 10, pages 663 - 71
    - FULLER et al., "Isolation and characterisation of a recombinant, precursor form of lysosomal acid alpha-glucosidase", European Journal of Biochemistry, (19950000), vol. 234, no. 3, doi:10.1111/j.1432-1033.1995.903_a.x, pages 903 - 909, XP000609446

DOI:   http://dx.doi.org/10.1111/j.1432-1033.1995.903_a.x
    - HUIE et al., "Increased occurrence of cleft lip in glycogen storage disease type II (GSDII): exclusion of a contiguous gene syndrome in two patients by presence of intragenic mutations including a novel nonsense mutation Gln58Stop", Am. J. Med. Genet., (19990000), vol. 85, no. 1, pages 5 - 8
    - HUIE et al., "Glycogen storage disease type II: identification of four novel missense mutations (D645N, G648S, R672W, R672Q) and two insertions/deletions in the acid alpha-glucosidase locus of patients of differing phenotype", Biochem. Biophys. Res. Commun., (19980000), vol. 244, no. 3, pages 921 - 7
    - NISHIYAMA et al., "Akt inactivation induces endoplasmic reticulum stress-independent autophagy in fibroblasts from patients with Pompe disease", Molecular genetics and metabolism, (20120000), vol. 107, doi:10.1016/j.ymgme.2012.09.011, pages 490 - 5, XP055108048

DOI:   http://dx.doi.org/10.1016/j.ymgme.2012.09.011
    - UMAPATHYSIVAM et al., "Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease", Clin Chim Acta., (20050000), vol. 361, no. 1-2, pages 191 - 8
    - DHITAL et al., "Mammalian mucosal a-glucosidases coordinate with a-amylase in the initial starch hydrolysis stage to have a role in starch digestion beyond glucogenesis", PLoS One, (20130425), vol. 8, no. 4, page e625462013
    - SIM et al., "Human intestinal maltase-glucoamylase: crystal structure of the N-terminal catalytic subunit and basis of inhibition and substrate specificity", J. Mol. Biol., (20080000), vol. 375, no. 3, doi:10.1016/j.jmb.2007.10.069, pages 782 - 92, XP022400118

DOI:   http://dx.doi.org/10.1016/j.jmb.2007.10.069
    - QUEZADA-CALVILLO et al., "Luminal starch substrate ''brake'' on maltase-glucoamylase activity is located within the glucoamylase subunit", J. Nutr., (20080000), vol. 138, no. 4, pages 685 - 92
    - RIDGWAY et al., "Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization", Protein Eng, (19960000), vol. 9, no. 7, doi:10.1093/protein/9.7.617, pages 617 - 621, XP002610995

DOI:   http://dx.doi.org/10.1093/protein/9.7.617
    - MAGA, J. A. et al., "Glycosylation-independent lysosomal targeting of acid a-glucosidase enhances muscle glycogen clearance in Pompe mice", Journal of Biological Chemistry, (20130000), vol. 288, doi:10.1074/jbc.M112.438663, pages 1428 - 1438, XP055305638

DOI:   http://dx.doi.org/10.1074/jbc.M112.438663
    - VALENZUELA et al., "High-throughput engineering of the mouse genome coupled with high-resolution expression analysis", Nature Biotechnology, (20030000), vol. 21, pages 652 - 659
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.